Puneet Kumar

Dr. Puneet Kumar

Department of Pharmacology, Central University of Punjab, Bathinda 151401, India
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in European Journal of Pharmacology
Verified
Journal Article
Closed access
AMAnkita Mehta
Ankita Mehta
MPMayank Prabhakar
Mayank Prabhakar
PKPuneet Kumar
Puneet Kumar
RDRahul Deshmukh
Rahul Deshmukh
PSP.L. Sharma
P.L. Sharma

1 September 2020 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Closed access
ASAkanksha Sharma
Akanksha Sharma
ASAnanya Shukla
Ananya Shukla
KAKriti Attri
Kriti Attri
MKMegha Kumar
Megha Kumar
PKPuneet Kumar
Puneet Kumar
NSNeha Singla
Neha Singla

7 June 2014 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
NGNidhi Goyal
Nidhi Goyal
ARAjay Rana
Ajay Rana
AAAbhilasha Ahlawat
Abhilasha Ahlawat
KBKrishna Reddy V. Bijjem
Krishna Reddy V. Bijjem
PKPuneet Kumar
Puneet Kumar

5 May 2016 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
OBOnkar Bedi
Onkar Bedi
VDVeena Dhawan
Veena Dhawan
PSP. L. Sharma
P. L. Sharma
PKPuneet Kumar
Puneet Kumar

10 June 2021 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
PKPuneet Kumar
Puneet Kumar
MKMandeep Kumar
Mandeep Kumar
OBOnkar Bedi
Onkar Bedi
MGManisha Gupta
Manisha Gupta
SKSachin Kumar
Sachin Kumar
SJSumit Jamwal
Sumit Jamwal

1 September 2006 in Behavioural Pharmacology
Verified
Journal Article
Closed access
PKPuneet Kumar
Puneet Kumar
SPSatyanaryana Sreenivasulu Venketswera Padi
Satyanaryana Sreenivasulu Venketswera Padi
PNPattipati Sreenivasulu Naidu
Pattipati Sreenivasulu Naidu
AKanil kumar
anil kumar
Huntington's disease is a progressive, degenerative disease characterized by abnormal body movements called chorea, and a reduction of various mental abilities. 3-Nitropropionic acid, an inhibitor of complex II of the electron transport chain, causes Huntington's disease-like symptoms in rodents. Recently, it has been reported that oxidative stress, which is one of the pathological hallmarks of various neurodegenerative disorders, also plays an important role in the pathogenesis of Huntington's disease. The present study was designed to investigate effects of resveratrol, an antioxidant with cyclooxygenase I inhibitory activity, in the 3-nitropropionic acid-induced model of Huntington's disease. Intraperitoneal administration of 3-nitropropionic acid (20 mg/kg for 4 days) caused significant loss of body weight, a decline in motor function (locomotor activity, movement pattern and vacuous chewing movements) and poor retention of memory. Repeated treatment with resveratrol (5 and 10 mg/kg, orally), once daily for a period of 8 days beginning 4 days prior to 3-nitropropionic acid administration, significantly improved the 3-nitropropionic acid-induced motor and cognitive impairment. Biochemical analysis revealed that systemic 3-nitropropionic acid administration significantly increased lipid peroxidation, nitrite levels, and depleted reduced glutathione levels, and decreased succinate dehydrogenase activity in the brains of rats. The results of the present study indicate that resveratrol (5 and 10 mg/kg, orally) significantly reversed 3-nitropropionic acid-induced motor and cognitive impairment, and that the beneficial effects of resveratrol might be attributed to its antioxidant activity.